When Dr. Maribel Parra and her team at the Josep Carreras Leukaemia Research Institute in Barcelona started asking why some patients with the most common blood cancer survive while others do not, they found their answer hiding inside our immune system's own training system. Their discovery: a protein called HDAC7 acts as a natural tumor suppressor — and when it goes missing, the disease becomes far more dangerous.
The study, published in The Journal of Immunology, focused on diffuse large B cell lymphoma (DLBCL), which accounts for roughly 40 percent of all non-Hodgkin lymphoma diagnoses worldwide. This cancer attacks the B cells that normally produce antibodies to protect us from infections. While many patients respond to standard chemotherapy, a significant number do not — and predicting who falls into which category has remained one of the field's persistent challenges.
To understand the cancer, the team first had to understand how healthy B cells develop. When our immune system encounters a new virus or bacterium, B cells rush to specialized structures in lymph nodes called germinal centers — essentially intensive training academies where they multiply, refine their targeting skills, and graduate into antibody factories. The IJC researchers, including Ainara Meler and Mar Gusi-Vives, discovered that HDAC7 serves as the master controller of this training process. In mouse experiments, removing HDAC7 from B cells caused the training to fail: cells became stuck in immature states and could not graduate into functional immune defenders.
The critical question was what happens to HDAC7 in cancer. When the team examined tumor samples and analyzed survival data from 292 DLBCL patients, they found that tumors with low levels of HDAC7 correlated strongly with poor outcomes. Patients whose cancers retained normal HDAC7 levels had significantly better prognoses. HDAC7, it turns out, functions as a biological brake on cancer — when it is lost, the disease accelerates.
But the most hopeful finding came from what happened when researchers restored HDAC7 in laboratory experiments. The cancer cells stopped multiplying and began to die. Tumors shrank dramatically when the protein was switched back on.
The implications for patients are twofold. First, measuring HDAC7 levels could become a new biomarker — a molecular signal to help doctors predict how a patient's disease will behave and tailor treatment accordingly. Second, because restoring HDAC7 kills cancer cells in the lab, it represents a potential therapeutic target for the patients who do not respond to existing therapies. If scientists can determine why HDAC7 disappears in tumors and find ways to reactivate it, new treatments could follow.
"We now understand that HDAC7 behaves like a natural tumor suppressor," the researchers noted. "Its loss contributes directly to cancer development and progression — and restoring it can reverse the process."
For the hundreds of thousands of people diagnosed with DLBCL each year, this tiny protein may represent a significant new front in the fight against blood cancer.